FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
Links shared publicly online about this topic.
- 343total visits
FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
View full resource at drugs.com
Tags: Healthcare, FDA, Tysabri
Most Recently Shared on April 23, 2011 at 11:06 pm By:
FDA Alert - Update of Healthcare Professional Information: Tysabri (natalizumab) - http://bit.ly/dV3ExV
FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on February 7, 2010 at 10:06 pm By:
FDA Alert - Revisions to Prescribing Information for Tysabri (natalizumab) - http://bit.ly/b2C46Z
Tysabri (Natalizumab): Update of Healthcare Professional Information
fda.gov — “Risk of developing progressive multifocal leukoencephalopathy (PML) increases with increasing duration of exposure to Tysabri.” View full resource at fda.gov
Most Recently Shared on February 5, 2010 at 4:43 pm By:
eyeonfda Pharma and Health Lawyer
FDA MedWatch updates on Tysabri - http://ow.ly/14hlb - PML Risk increases with number of infusions.
Advertisement
